Russian Heart Failure Journal 2011year Reducing cardiovascular risk: focus on ACE inhibitor ramipril


To access this material please log in or register

Register Authorize
2011/

Reducing cardiovascular risk: focus on ACE inhibitor ramipril

Napalkov D. A., Zhilenko A. V., Sulimov V. A.
State Budgetary Educational Institution “I. M. Sechenov First Moscow State Medical University” of the RF Ministry of Health Care, Trubetskaya 8, Bld. 2, Moscow 119991

Keywords: ACE inhibitors, coronary artery disease, ramipril, cardiovascular risk

DOI: 10.18087/ rhfj.2011.4.1545

The review analyzes clinical trials studying the effects of ACE inhibitor ramipril at different stages of cardiovascular continuum. Also results of own trial of Pyramil (ramipril) in patients with ischemic chronic heart failure associated with hypertension and diabetes mellitus are discussed. The drug effectively normalizes blood pressure in patients with hypertension and chronic heart failure with reduced systolic LV function and has good tolerability profile.
  1. Гиляревский С. Р., Орлов В. А., Середенина Е. М. Самоконтроль и самолечение больных с хронической сердечной недостаточностью: границы эффективности и безопасности. Журнал Сердечная Недостаточность. 2002;3 (5):237–244.
  2. Национальные Рекомендации ВНОК И ОССН по диагностике и лечению ХСН (второй пересмотр). Журнал Сердечная Недостаточность. 2007;8 (1):4–41.
  3. Беленков Ю. Н. Б Мареев В. Ю. Принципы рационального лечения сердечной недостаточности. – М.: «Медиа Медика», 2000. – 266 с.
  4. Никифоров В. С., Свистов А. С. Современные направления применения ингибиторов ангиотензин-превращающего фермента в клиниче­ской практике. ФАРМиндекс- Практик. 2005;7:21–31.
  5. Hunt SA, Baker DW, Chin MH et al. ACC / AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the International Society for Heart and Lung Transplantation; Endorsed by the Heart Failure Society of America. Circulation. 2001;104 (24):2996–3007.
  6. Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chro­nic heart failure. Task force for the diagnosis and treatment of chronic heart failure, European Society of Cardiology. Eur Heart J. 2001;22 (17):1527–1560.
  7. Heart Failure Society of America (HFSA) practice guidelines. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction--pharmacological approaches. J Card Fail. 1999;5 (4):357–382.
  8. Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342 (3):145–153.
  9. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342 (8875):821–828.
  10. Hall AS, Murray GD, Ball SG. Follow-up study of patients randomly allocated ramipril or placebo for heart failure after myocardial infarction: AIRE Extension (AIREX) study. Lancet. 1997;349 (9064):1493–1497.
  11. Kaplan NM. The CARE Study: a postmarketing evaluation of ramipril in 11,100 patients. The Clinical Altace Real-World Efficacy (CARE) Investigators. Clin Ther. 1996;18 (4):658–670.
  12. Lièvre M, Guéret P, Gayet C et al. Ramipril-induced regression of left ventricular hypertrophy in treated hypertensive individuals. HYCAR Study Group. Hypertension. 1995;25 (1):92–97.
  13. Agabiti-Rosei E, Ambrosioni E, Dal Palù C et al. ACE inhibitor ramipril is more effective than the beta-blocker atenolol in reducing left ventri­cular mass in hypertension. Results of the RACE (ramipril cardioprotective evaluation) study on behalf of the RACE study group. J Hypertens. 1995;13 (11):1325–34.
  14. Wienbergen H, Schiele R, Gitt AK et al. Impact of ramipril versus other angiotensin-converting enzyme inhibitors on outcome of unselected patients with ST-elevation acute myocardial infarction. Am J Cardiol. 2002;90 (10):1045–1049.
  15. Knoller-Hansen L, Steffensen R, Grande P. The Angiotensin-converting Enzyme Inhibition Post Revascularization Study (APRES). J Am Coll Cardiol. 2000;35 (4):881–888.
  16. Lonn E, Yusuf S, Dzavik V et al. Effects of ramipril and vitamin E on athe­rosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation. 2001;103 (7):919–925.
  17. Mancini GB, Henry GC, Macaya C et al. Angiotensin converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation. 1996;94 (3):258–265.
  18. Ruggenenti P, Perna A, Gherardi G et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet. 1999;354 (9176):359–364.
  19. ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358 (15):1547–1559.
Napalkov D. A., Zhilenko A. V., Sulimov V. A. Reducing cardiovascular risk: focus on ACE inhibitor ramipril. Russian Heart Failure Journal. 2011;12(4):228-231.

To access this material please log in or register

Register Authorize
Ru En